A Phase 2, Randomized, Placebo-controlled, Parallel Group, Multicenter 12-week Study With a 52-week Extension to Evaluate the Efficacy and Safety of Two Doses of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid and/or Obeticholic Acid Treatment
Latest Information Update: 30 May 2025
At a glance
- Drugs Pemafibrate (Primary)
- Indications Cholangitis
- Focus Therapeutic Use
- Sponsors Kowa Pharmaceutical
Most Recent Events
- 23 May 2025 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2025 Planned End Date changed from 8 Apr 2026 to 1 Aug 2026.
- 26 Feb 2025 Planned primary completion date changed from 9 Apr 2025 to 1 Aug 2025.